Tasly Pharmaceutical Selects ICON as it Seeks First FDA Approval of a Traditional Chinese Medicine  
11/21/2011 8:33:39 AM

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Tasly Pharmaceuticals ( 600535, SH)for the company’s global Phase III T89 trial. T89, also known as Dantonic® pill, aims to become the first traditional Chinese medicine to receive FDA approval in the United States.